AngioDynamics, Inc. designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company's devices are used in minimally invasive, image-guided procedures. The Company offers products within three product groupings: Peripheral Vascular, Vascular Access and Oncology/Surgery. The Company's Peripheral Vascular products include Fluid Management, Venous, Thrombus Management, as well as other core products. The Company's BioFlo products incorporate Endexo Technology into the manufacturing and design of its Vascular Access products. Its Oncology/Surgery product offerings include its Microwave Ablation products, Radiofrequency Ablation (RFA) and its NanoKnife product lines.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Medical Supplies
- Sub-Industry: Health Care Equipment
- Symbol: NASDAQ:ANGO
- CUSIP: 03475V10
- Web: www.angiodynamics.com
Capitalization:- Market Cap: $601.72 million
- Outstanding Shares: 36,780,000
Average Prices:- 50 Day Moving Avg: $16.02
- 200 Day Moving Avg: $16.22
- 52 Week Range: $14.80 - $18.18
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: 22.11
- P/E Growth: 1.97
Sales & Book Value:- Annual Revenue: $356.15 million
- Price / Sales: 1.69
- Book Value: $14.46 per share
- Price / Book: 1.13
Profitability:- EBIDTA: $49.52 million
- Net Margins: 2.00%
- Return on Equity: 5.19%
- Return on Assets: 3.79%
Debt:- Debt-to-Equity Ratio: 0.18%
- Current Ratio: 2.21%
- Quick Ratio: 1.43%
Misc:- Average Volume: 239,711 shs.
- Beta: 1.15
- Short Ratio: 9.22
Frequently Asked Questions for AngioDynamics (NASDAQ:ANGO)
What is AngioDynamics' stock symbol?
AngioDynamics trades on the NASDAQ under the ticker symbol "ANGO."
How were AngioDynamics' earnings last quarter?
AngioDynamics, Inc. (NASDAQ:ANGO) issued its earnings results on Tuesday, July, 18th. The company reported $0.19 earnings per share for the quarter, topping the consensus estimate of $0.16 by $0.03. The company had revenue of $86.90 million for the quarter, compared to analyst estimates of $90.72 million. AngioDynamics had a return on equity of 5.19% and a net margin of 2.00%. The business's revenue was down 7.0% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.19 EPS. View AngioDynamics' Earnings History.
When will AngioDynamics make its next earnings announcement?
What guidance has AngioDynamics issued on next quarter's earnings?
AngioDynamics issued an update on its FY18 earnings guidance on Tuesday, July, 18th. The company provided earnings per share guidance of $0.64-0.68 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.68. The company issued revenue guidance of $352-359 million, compared to the consensus revenue estimate of $357.75 million.
Where is AngioDynamics' stock going? Where will AngioDynamics' stock price be in 2017?
5 equities research analysts have issued 1 year target prices for AngioDynamics' shares. Their forecasts range from $16.00 to $21.00. On average, they expect AngioDynamics' stock price to reach $18.40 in the next year. View Analyst Ratings for AngioDynamics.
What are analysts saying about AngioDynamics stock?
Here are some recent quotes from research analysts about AngioDynamics stock:
- 1. According to Zacks Investment Research, "AngioDynamics reported a mixed fourth quarter of fiscal 2017, wherein adjusted earnings beat the Zacks Consensus Estimate while revenues missed the same. The year-over-year decline at the company’s Peripheral Vascular, Vascular Access and Oncology & Surgery business segments marred revenues. Furthermore, the company expects earnings to fall sequentially in FY18. Lackluster performance by the oncology segment was primarily due to market withdrawal of the company’s flagship Acculis Microwave Tissue Ablation System, which also marred international sales. AngioDynamics has a high outstanding debt level at the end of the fourth quarter. This is likely to impose certain operating and financial restrictions, limiting the company’s core business strategies. Over the last one year, AngioDynamics has underperformed the broader industry in terms of price. However, growth in the core Angiographic Catheter business holds promise." (7/20/2017)
- 2. Cantor Fitzgerald analysts commented, "F3Q17 Result Summary. F3Q17 total revenues of $85.6M (down 2.0% y/y), was $3.2M below our estimate of $88.8M and $2.7M below FactSet consensus of $88.3M." (3/30/2017)
Who are some of AngioDynamics' key competitors?
Some companies that are related to AngioDynamics include Quidel Corporation (QDEL), ABAXIS (ABAX), Global Blood Therapeutics (GBT), Dermira (DERM), Natus Medical Incorporated (BABY), Momenta Pharmaceuticals (MNTA), Medpace Holdings (MEDP), The Ensign Group (ENSG), Genomic Health (GHDX), Xencor (XNCR), Aimmune Therapeutics (AIMT), Quality Systems (QSII), Amarin Corporation PLC (AMRN), LHC Group (LHCG), Esperion Therapeutics (ESPR), K2M Group Holdings (KTWO), Cardiovascular Systems (CSII) and Insmed (INSM).
Who are AngioDynamics' key executives?
AngioDynamics' management team includes the folowing people:
- Howard W. Donnelly, Independent Chairman of the Board
- James C. Clemmer, President, Chief Executive Officer, Director
- Michael Greiner, Chief Financial Officer, Executive Vice President
- Gary Barrett, Senior Vice President,Quality and Regulatory Affairs
- Ben Davis, Senior Vice President, Business Development
- Barbara Kucharczyk, Senior Vice President-Global Operations
- Stephen A. Trowbridge, Senior Vice President, General Counsel
- Eileen O'Shea Auen, Director
- Jan Stern Reed, Director
- David F. Burgstahler, Independent Director
Who owns AngioDynamics stock?
AngioDynamics' stock is owned by many different of institutional and retail investors. Top institutional investors include Peregrine Capital Management LLC (2.04%), Fenimore Asset Management Inc. (1.57%), Bank of Montreal Can (0.71%), Acadian Asset Management LLC (0.62%), Spark Investment Management LLC (0.38%) and Russell Investments Group Ltd. (0.34%). Company insiders that own AngioDynamics stock include Avista Capital Partners Gp, Ll, Charles R Greiner, David F Burgstahler, James C Clemmer, Jan Stern Reed and Stephen A Trowbridge. View Institutional Ownership Trends for AngioDynamics.
Who sold AngioDynamics stock? Who is selling AngioDynamics stock?
AngioDynamics' stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Acadian Asset Management LLC and Perkins Capital Management Inc.. Company insiders that have sold AngioDynamics stock in the last year include Avista Capital Partners Gp, Ll and David F Burgstahler. View Insider Buying and Selling for AngioDynamics.
Who bought AngioDynamics stock? Who is buying AngioDynamics stock?
AngioDynamics' stock was purchased by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, Bank of Montreal Can, Fenimore Asset Management Inc., Bowling Portfolio Management LLC, Hartford Investment Management Co., Campbell & CO Investment Adviser LLC, GW&K Investment Management LLC and First Quadrant L P CA. Company insiders that have bought AngioDynamics stock in the last two years include James C Clemmer and Jan Stern Reed. View Insider Buying and Selling for AngioDynamics.
How do I buy AngioDynamics stock?
Shares of AngioDynamics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is AngioDynamics' stock price today?
One share of AngioDynamics stock can currently be purchased for approximately $16.36.
MarketBeat Community Rating for AngioDynamics (NASDAQ ANGO)MarketBeat's community ratings are surveys of what our community members think about AngioDynamics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for AngioDynamics (NASDAQ:ANGO) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 2 Hold Ratings, 3 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.60) |
| Consensus Price Target: | $18.40 (12.47% upside) |
Analysts' Ratings History for AngioDynamics (NASDAQ:ANGO)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 7/19/2017 | Barclays PLC | Lower Price Target | Equal Weight | $17.00 -> $16.00 | Low |  |
| 7/18/2017 | Canaccord Genuity | Reiterated Rating | Hold | $17.00 | Medium | |
| 7/4/2017 | Cantor Fitzgerald | Boost Price Target | Overweight | $20.00 -> $21.00 | Low | |
| 4/1/2017 | Craig Hallum | Set Price Target | Buy | $20.00 | Low | |
| 9/12/2016 | KeyCorp | Set Price Target | Buy | $18.00 | N/A | |
| 4/8/2016 | Piper Jaffray Companies | Initiated Coverage | Neutral | $12.00 | N/A | |
| 11/10/2015 | Raymond James Financial, Inc. | Downgrade | Outperform -> Market Perform | | N/A | |
| 9/23/2015 | Sidoti | Initiated Coverage | Neutral | $14.50 | N/A | |
(Data available from 7/27/2015 forward)
Earnings History for AngioDynamics (NASDAQ:ANGO)Earnings History by Quarter for AngioDynamics (NASDAQ ANGO)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 10/3/2017 | | $0.16 | | | | | N/A | |
| 7/18/2017 | Q4 2017 | $0.16 | $0.19 | $90.72 million | $86.90 million | View | N/A | |
| 3/30/2017 | Q3 2017 | $0.15 | $0.19 | $88.29 million | $85.60 million | View | N/A | |
| 1/6/2017 | Q217 | $0.16 | $0.19 | $91.09 million | $89.00 million | View | Listen | |
| 10/5/2016 | Q117 | $0.13 | $0.17 | $86.09 million | $88.10 million | View | N/A | |
| 7/13/2016 | Q416 | $0.16 | $0.19 | $88.64 million | $93.40 million | View | Listen | |
| 4/7/2016 | Q3 | $0.14 | $0.15 | $85.43 million | $87.40 million | View | Listen | |
| 1/7/2016 | Q216 | $0.14 | $0.14 | $88.67 million | $89.20 million | View | N/A | |
| 10/8/2015 | Q116 | $0.11 | $0.11 | $84.70 million | $83.70 million | View | N/A | |
| 7/16/2015 | Q415 | $0.14 | $0.14 | $91.67 million | $90.90 million | View | Listen | |
| 4/9/2015 | Q315 | $0.15 | $0.12 | $88.69 million | $86.60 million | View | N/A | |
| 1/8/2015 | Q215 | $0.15 | $0.17 | $90.90 million | $92.10 million | View | N/A | |
| 10/9/2014 | Q115 | $0.11 | $0.16 | $85.35 million | $87.30 million | View | Listen | |
| 7/23/2014 | Q414 | $0.12 | $0.18 | $93.65 million | $94.07 million | View | Listen | |
| 4/9/2014 | Q314 | $0.09 | $0.16 | $86.85 million | $88.20 million | View | Listen | |
| 1/9/2014 | Q2 | $0.07 | $0.14 | $87.54 million | $88.60 million | View | Listen | |
| 10/10/2013 | Q114 | $0.03 | $0.04 | $82.54 million | $83.60 million | View | N/A | |
| 7/11/2013 | Q4 2013 | $0.06 | $0.07 | $86.43 million | $90.00 million | View | N/A | |
| 4/8/2013 | Q3 2013 | $0.05 | $0.08 | $81.70 million | $81.60 million | View | N/A | |
| 1/3/2013 | Q2 2013 | $0.09 | $0.10 | $87.40 million | $87.00 million | View | N/A | |
| 10/8/2012 | Q113 | $0.09 | $0.10 | $84.35 million | $83.40 million | View | N/A | |
| 7/12/2012 | | $0.08 | $0.09 | | | View | N/A | |
| 4/4/2012 | | $0.07 | $0.09 | | | View | N/A | |
| 1/5/2012 | | $0.12 | $0.13 | | | View | N/A | |
| 10/6/2011 | | $0.09 | $0.08 | | | View | N/A | |
| 7/14/2011 | | $0.10 | $0.11 | | | View | N/A | |
| 4/5/2011 | | $0.12 | $0.15 | | | View | N/A | |
| 1/4/2011 | | $0.12 | $0.13 | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for AngioDynamics (NASDAQ:ANGO)2017 EPS Consensus Estimate: $0.61
2018 EPS Consensus Estimate: $0.71
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 1 | $0.13 | $0.13 | $0.13 |
| Q2 2017 | 1 | $0.17 | $0.17 | $0.17 |
| Q3 2017 | 2 | $0.15 | $0.16 | $0.16 |
| Q4 2017 | 2 | $0.14 | $0.16 | $0.15 |
| Q1 2018 | 2 | $0.14 | $0.18 | $0.16 |
| Q2 2018 | 2 | $0.15 | $0.17 | $0.16 |
| Q3 2018 | 2 | $0.18 | $0.23 | $0.21 |
| Q4 2018 | 2 | $0.15 | $0.21 | $0.18 |
(Data provided by Zacks Investment Research)
Dividend History for AngioDynamics (NASDAQ:ANGO)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for AngioDynamics (NASDAQ:ANGO)Insider Ownership Percentage: 1.88%
Institutional Ownership Percentage: 84.78%
Insider Trades by Quarter for AngioDynamics (NASDAQ:ANGO)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 7/24/2017 | Jan Stern Reed | Director | Buy | 316 | $16.00 | $5,056.00 | |
| 7/21/2017 | James C Clemmer | CEO | Buy | 5,000 | $15.79 | $78,950.00 | |
| 7/20/2017 | James C Clemmer | CEO | Buy | 20,000 | $15.64 | $312,800.00 | |
| 4/12/2017 | Avista Capital Partners Gp, Ll | Major Shareholder | Sell | 2,350,000 | $16.00 | $37,600,000.00 | |
| 8/5/2016 | Avista Capital Partners Gp, Ll | Major Shareholder | Sell | 2,241,000 | $14.62 | $32,763,420.00 | |
| 8/5/2016 | David F Burgstahler | Director | Sell | 2,250,000 | $14.62 | $32,895,000.00 | |
| 5/6/2016 | Charles R Greiner | VP | Sell | 3,508 | $12.31 | $43,183.48 | |
| 4/25/2016 | Stephen A Trowbridge | SVP | Sell | 12,940 | $12.30 | $159,162.00 | |
| 4/14/2014 | Matthew Kapusta | SVP | Buy | 1,000 | $13.90 | $13,900.00 | |
| 10/18/2013 | Vincent Bucci | Director | Buy | 5,000 | $15.20 | $76,000.00 | |
| 10/17/2013 | Howard W Donnelly | Director | Sell | 20,000 | $15.06 | $301,200.00 | |
| 7/22/2013 | Kevin J Gould | Director | Buy | 2,700 | $12.00 | $32,400.00 | |
| 5/9/2013 | Charles R Greiner | VP | Sell | 1,495 | $10.38 | $15,518.10 | |
| 3/12/2013 | Vincent Bucci | Director | Buy | 85,000 | $10.77 | $915,450.00 | |
| 2/14/2013 | Vincent Bucci | Director | Buy | 2,000 | $12.17 | $24,340.00 | |
| 1/11/2013 | Kevin J Gould | Director | Buy | 2,700 | $11.58 | $31,266.00 | |
| 11/5/2012 | Jeffrey Gold | Director | Buy | 1,000 | $10.56 | $10,560.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for AngioDynamics (NASDAQ:ANGO)
Latest Headlines for AngioDynamics (NASDAQ:ANGO)
| Source: |
|
| Date | Headline |
|---|
 | INVESTOR ALERT: Monteverde & Associates PC Announces an Investigation of AngioDynamics, Inc. - ANGO
finance.yahoo.com - July 26 at 4:27 PM |
 | Teleflex (TFX) & AngioDynamics (ANGO) Head-To-Head Analysis
www.americanbankingnews.com - July 25 at 4:24 PM |
| Financial Comparison: AngioDynamics (NASDAQ:ANGO) vs. Teleflex (TFX)
www.americanbankingnews.com - July 25 at 8:30 AM |
| INVESTOR ALERT: Goldberg Law PC Announces an Investigation of AngioDynamics, Inc.
finance.yahoo.com - July 24 at 11:17 PM |
| Teleflex (TFX) and AngioDynamics (ANGO) Head-To-Head Survey
www.americanbankingnews.com - July 24 at 10:18 PM |
| James C. Clemmer Purchases 5,000 Shares of AngioDynamics, Inc. (ANGO) Stock
www.americanbankingnews.com - July 21 at 7:51 PM |
| James C. Clemmer Buys 20,000 Shares of AngioDynamics, Inc. (NASDAQ:ANGO) Stock
www.americanbankingnews.com - July 21 at 7:31 PM |
| AngioDynamics, Inc. (ANGO) Forecasted to Post FY2019 Earnings of $0.69 Per Share
www.americanbankingnews.com - July 21 at 4:16 PM |
| AngioDynamics, Inc. (NASDAQ:ANGO) to Post Q4 2018 Earnings of $0.21 Per Share, KeyCorp Forecasts
www.americanbankingnews.com - July 21 at 4:16 PM |
| AngioDynamics, Inc. (NASDAQ:ANGO) Cut to Sell at Zacks Investment Research
www.americanbankingnews.com - July 20 at 2:34 PM |
| Craig Hallum Comments on AngioDynamics, Inc.'s FY2018 Earnings (ANGO)
www.americanbankingnews.com - July 20 at 1:48 PM |
| AngioDynamics, Inc. (ANGO) Forecasted to Post Q1 2018 Earnings of $0.14 Per Share
www.americanbankingnews.com - July 20 at 12:42 PM |
| AngioDynamics, Inc. breached its 50 day moving average in a Bearish Manner : ANGO-US : July 19, 2017
finance.yahoo.com - July 19 at 5:04 PM |
| Barclays PLC Cuts AngioDynamics, Inc. (NASDAQ:ANGO) Price Target to $16.00
www.americanbankingnews.com - July 19 at 3:05 PM |
| Edited Transcript of ANGO earnings conference call or presentation 18-Jul-17 12:00pm GMT
finance.yahoo.com - July 19 at 3:27 AM |
 | AngioDynamics, Inc. (ANGO)
seekingalpha.com - July 18 at 10:25 PM |
| SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of AngioDynamics, Inc.
finance.yahoo.com - July 18 at 10:25 PM |
| ANGIODYNAMICS (ANGO) INVESTOR ALERT: Legal Investigation for Potential Securities Law Violations
finance.yahoo.com - July 18 at 10:25 PM |
| IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces an Investigation of AngioDynamics, Inc. and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - July 18 at 10:25 PM |
| AngioDynamics, Inc. (NASDAQ:ANGO) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - July 18 at 6:56 PM |
| AngioDynamics Reports Fiscal 2017 Fourth Quarter and Full-Year Results
finance.yahoo.com - July 18 at 5:23 PM |
| AngioDynamics Reports Fiscal 2017 Fourth Quarter and Full-Year Results
finance.yahoo.com - July 18 at 5:23 PM |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AngioDynamics, Inc. - ANGO
finance.yahoo.com - July 18 at 5:23 PM |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AngioDynamics, Inc. - ANGO
finance.yahoo.com - July 18 at 5:23 PM |
| SHAREHOLDER ALERT: Goldberg Law PC Announces an Investigation of AngioDynamics, Inc.
finance.yahoo.com - July 18 at 5:23 PM |
| SHAREHOLDER ALERT: Goldberg Law PC Announces an Investigation of AngioDynamics, Inc.
finance.yahoo.com - July 18 at 5:23 PM |
| SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of AngioDynamics, Inc. (ANGO)
finance.yahoo.com - July 18 at 5:23 PM |
| SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of AngioDynamics, Inc. (ANGO)
finance.yahoo.com - July 18 at 5:23 PM |
| ANGIODYNAMICS INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In AngioDynamics, Inc. To Contact The Firm
finance.yahoo.com - July 18 at 5:23 PM |
| ANGIODYNAMICS INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In AngioDynamics, Inc. To Contact The Firm
finance.yahoo.com - July 18 at 5:23 PM |
| IMPORTANT INVESTOR ALERT: Lundin Law PC Announces an Investigation of AngioDynamics, Inc.
finance.yahoo.com - July 18 at 5:23 PM |
| IMPORTANT INVESTOR ALERT: Lundin Law PC Announces an Investigation of AngioDynamics, Inc.
finance.yahoo.com - July 18 at 5:23 PM |
| AngioDynamics reports 4Q loss
finance.yahoo.com - July 18 at 5:23 PM |
| AngioDynamics reports 4Q loss
finance.yahoo.com - July 18 at 5:23 PM |
| Canaccord Genuity Reiterates "Hold" Rating for AngioDynamics, Inc. (NASDAQ:ANGO)
www.americanbankingnews.com - July 18 at 4:17 PM |
| AngioDynamics, Inc. (NASDAQ:ANGO) Announces Earnings Results
www.americanbankingnews.com - July 18 at 11:35 AM |
| AngioDynamics, Inc. (ANGO) Updates FY18 Earnings Guidance
www.americanbankingnews.com - July 18 at 11:34 AM |
| Financial Comparison: AngioDynamics (ANGO) and Teleflex (TFX)
www.americanbankingnews.com - July 14 at 6:36 PM |
| AngioDynamics, Inc. (NASDAQ:ANGO) Set to Announce Earnings on Tuesday
www.americanbankingnews.com - July 14 at 7:10 AM |
| Zacks: Analysts Anticipate AngioDynamics, Inc. (NASDAQ:ANGO) Will Post Quarterly Sales of $90.76 Million
www.americanbankingnews.com - July 13 at 10:00 AM |
| AngioDynamics, Inc. (ANGO) Expected to Announce Earnings of $0.16 Per Share
www.americanbankingnews.com - July 11 at 4:20 PM |
| AngioDynamics (NASDAQ:ANGO) vs. Teleflex (TFX) Critical Survey
www.americanbankingnews.com - July 8 at 12:28 PM |
 | AngioDynamics to Report Fiscal 2017 Fourth Quarter and Full-Year Financial Results
feeds.benzinga.com - July 7 at 6:25 AM |
| Head-To-Head Contrast: Teleflex (TFX) vs. AngioDynamics (NASDAQ:ANGO)
www.americanbankingnews.com - July 1 at 8:12 AM |
| Contrasting Becton, Dickinson and Company (BDX) & AngioDynamics (ANGO)
www.americanbankingnews.com - June 29 at 12:04 PM |
| Brokers Set Expectations for AngioDynamics, Inc.'s FY2018 Earnings (ANGO)
www.americanbankingnews.com - June 26 at 11:28 AM |
| AngioDynamics, Inc. (ANGO) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - June 23 at 5:08 PM |
| Brokerages Anticipate AngioDynamics, Inc. (ANGO) Will Announce Quarterly Sales of $90.76 Million
www.americanbankingnews.com - June 17 at 8:48 AM |
| ETFs with exposure to AngioDynamics, Inc. : June 15, 2017
finance.yahoo.com - June 15 at 5:12 PM |
| AngioDynamics, Inc. – Value Analysis (NASDAQ:ANGO) : June 15, 2017
finance.yahoo.com - June 15 at 5:12 PM |
AngioDynamics (ANGO) Chart for Thursday, July, 27, 2017
